基本信息
浏览量:38
职业迁徙
个人简介
David Kallend is currently Chief Scientific Officer and Chief Medical Officer of DalCor Pharmaceuticals and Chief Medical Officer of LIB Therapeutics. David does research in lipidology, diabetology, Internal Medicine (General Medicine), imaging and Cardiology. His current projects are dalcetrapib and lerodalcibep (LIB003).
研究兴趣
论文共 154 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ulrich Laufs, Manuela Licka,Emil Asprusten,Bertrand Cariou,Nicholas Jacobsen,Fernando Civeira Murillo, Jeffrey Vest,David Kallend,Evan Stein
Atherosclerosis (2024): 118406-118406
Dean Kereiakes,Nyda Fourie, Johannes Engelbrecht,Lesley Burgess, Jane Kerr, Zafir Yalim, Jeffrey Vest,David Kallend,Evan Stein
ATHEROSCLEROSIS (2024)
Eric Q. Klug, Sara Llerena,Lesley J. Burgess,Nyda Fourie,Russell Scott, Jeff Vest,Kate Caldwell,David Kallend,Evan A. Stein
Frederick J Raal,Vimal Mehta,Meral Kayikcioglu,Dirk J Blom,Preeti Gupta,Ronen Durst,Emil A Asprusten,Traci Turner,El Mustapha Bahassi, Jeffrey Vest,Kate Caldwell,David Kallend, Evan A Stein
Circulationno. Suppl_1 (2023)
加载更多
作者统计
#Papers: 147
#Citation: 6050
H-Index: 38
G-Index: 77
Sociability: 6
Diversity: 3
Activity: 48
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn